Advanced Search

Home Health & Hospice Week

Investigations into Amedisys Inc.'s therapy

Published on Tue Oct 26, 2010

Investigations into Amedisys Inc.'s therapy provision by The Wall Street Journal, U.S. Senate, Securities and Exchange Commission, Department of Justice, and others seem to be taking their toll. The Baton Rouge, La.-based national chain reported a 40 percent drop in profits for the quarter ended Sept. 30, compared to the year-ago quarter. Amedisys reported net income of $21.8 million for the quarter, down from $35.9 million in 2009. Net revenue grew 4 percent in the period, from $388.3 million to $404.7 million. "The quarter's results reflect the volume fall-off we began experiencing in the second quarter," CEO William Borne says in a release. "We have implemented a number of initiatives to better align our cost structure with current volume and improve our revenue moving forward."
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Home Health & Hospice Week

View All